Keloid disease carries a burden beyond skin deep

A raised scar that will not stop growing. That is the simplest description of a keloid — but the Journal of Investigative Dermatology argues the simplest description is also the most misleading one.

Keloids form when the body's wound-healing response does not switch off. According to the journal, the condition involves sustained inflammation, abnormal activation of fibroblasts, and an excessive build-up of extracellular matrix tissue that spreads well beyond the original wound boundary. The result is a scar that keeps expanding into healthy skin.

The clinical picture, as the journal describes it, extends far past appearance. People living with keloids report severe pain and persistent itching. In some cases, the journal notes, the tissue can restrict movement through contractures — a tightening of the skin that limits how a joint bends or a limb functions.

A chronic disease, not a cosmetic outcome

The journal is direct on this point: keloids are not primarily a cosmetic concern. The paper describes the condition as a debilitating chronic disease with life-altering consequences for millions worldwide.

The psychosocial weight the journal documents is specific. Researchers reported associations with anxiety, depression, stigma, and a measurably reduced quality of life. These are not secondary effects — the journal positions them as central to understanding what keloid disease actually is.

For the albinism community, this framing matters. People with albinism already navigate heightened skin vulnerability: UV exposure, wound sensitivity, and in many contexts, limited access to dermatological care. Any condition that compromises skin integrity further — and that is routinely dismissed as cosmetic — sits at a familiar intersection of underdiagnosis and undertreatment.

The journal's call is directed at investigative dermatology as a field. Researchers say there is a significant epidemiological gap: the populations most affected by keloids, which include people of African and Asian descent, remain underrepresented in the clinical literature that shapes treatment standards.

Without that data, the journal argues, the gap between who carries the burden of this disease and who benefits from research into it will remain wide.